Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

The Polyethylene Glycol Market is projected to grow from USD 3.94 billion in 2024 to USD 5.31 billion by 2029, at a CAGR of 6 ...